In-transit melanoma: the role of alkylating-agent resistance in regional therapy.


BACKGROUND Regional perfusion treatments for melanoma, using the alkylating agent melphalan, show variable responses in magnitude and duration. Surprisingly, the potential contribution of alkylating-agent resistance mechanisms to diminish tumor responses, especially the crucial cellular detoxifying system formed by glutathione (GSH) and its associated… (More)


  • Presentations referencing similar topics